Prevalence of myocardial fibrosis by left ventricular assist device apical core biopsy and correlation with other markers of myocardial recovery

Research output: Contribution to journalArticle

Abstract

Myocardial fibrosis identified by apical core pathology at the time of left ventricular assist device (LVAD) implantation may add information regarding myocardial recovery potential. In this analysis, we report the prevalence of myocardial fibrosis by cardiomyopathy type and its association with other known markers of left ventricular recovery. Left ventricular assist device core pathology was reviewed on 332 patients who underwent LVAD implantation at a single institution between 2005 and 2016. Baseline clinical and echocardiographic characteristics were compared among patients with and without myocardial fibrosis by cardiomyopathy type. Among the 332 LVAD core specimens, myocardial fibrosis was present in 79%. Myocardial fibrosis was more common in ischemic than in nonischemic patients (90% vs. 66%; p < 0.001). Patients with fibrosis were older than those without (58 ± 12 vs. 55 ± 19; p < 0.05). Among the nonischemic cardiomyopathy cases, those with fibrosis were more likely to have an implantable cardioverter defibrillator (ICD) 81% and to be diabetic 81%. Fibrosis was not associated with left ventricular end-diastolic diameter (LVEDD), creatinine, or N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). Myocardial fibrosis by apical core biopsy correlated with several known markers of left ventricular recovery including cardiomyopathy type, age, and presence of an ICD. In nonischemic cardiomyopathy patients, the degree of myocardial fibrosis may add information regarding recovery potential.

Original languageEnglish (US)
Pages (from-to)123-126
Number of pages4
JournalASAIO Journal
Volume65
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Biopsy
Fibrosis
Implantable cardioverter defibrillators
Recovery
Pathology
Cardiomyopathies
Brain Natriuretic Peptide
Implantable Defibrillators
Brain
Creatinine

Keywords

  • biomarkers
  • fibrosis
  • left ventricular assist device
  • myocardial recovery

PubMed: MeSH publication types

  • Journal Article

Cite this

@article{07deb52beb574d458c01039364b70db4,
title = "Prevalence of myocardial fibrosis by left ventricular assist device apical core biopsy and correlation with other markers of myocardial recovery",
abstract = "Myocardial fibrosis identified by apical core pathology at the time of left ventricular assist device (LVAD) implantation may add information regarding myocardial recovery potential. In this analysis, we report the prevalence of myocardial fibrosis by cardiomyopathy type and its association with other known markers of left ventricular recovery. Left ventricular assist device core pathology was reviewed on 332 patients who underwent LVAD implantation at a single institution between 2005 and 2016. Baseline clinical and echocardiographic characteristics were compared among patients with and without myocardial fibrosis by cardiomyopathy type. Among the 332 LVAD core specimens, myocardial fibrosis was present in 79{\%}. Myocardial fibrosis was more common in ischemic than in nonischemic patients (90{\%} vs. 66{\%}; p < 0.001). Patients with fibrosis were older than those without (58 ± 12 vs. 55 ± 19; p < 0.05). Among the nonischemic cardiomyopathy cases, those with fibrosis were more likely to have an implantable cardioverter defibrillator (ICD) 81{\%} and to be diabetic 81{\%}. Fibrosis was not associated with left ventricular end-diastolic diameter (LVEDD), creatinine, or N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). Myocardial fibrosis by apical core biopsy correlated with several known markers of left ventricular recovery including cardiomyopathy type, age, and presence of an ICD. In nonischemic cardiomyopathy patients, the degree of myocardial fibrosis may add information regarding recovery potential.",
keywords = "biomarkers, fibrosis, left ventricular assist device, myocardial recovery",
author = "Schultz, {Jessica N} and Ranjit John and Martin, {Cindy M} and Kamdar, {Forum D} and Thenappan Thenappan and Cogswell, {Rebecca J}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/MAT.0000000000000774",
language = "English (US)",
volume = "65",
pages = "123--126",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Prevalence of myocardial fibrosis by left ventricular assist device apical core biopsy and correlation with other markers of myocardial recovery

AU - Schultz, Jessica N

AU - John, Ranjit

AU - Martin, Cindy M

AU - Kamdar, Forum D

AU - Thenappan, Thenappan

AU - Cogswell, Rebecca J

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Myocardial fibrosis identified by apical core pathology at the time of left ventricular assist device (LVAD) implantation may add information regarding myocardial recovery potential. In this analysis, we report the prevalence of myocardial fibrosis by cardiomyopathy type and its association with other known markers of left ventricular recovery. Left ventricular assist device core pathology was reviewed on 332 patients who underwent LVAD implantation at a single institution between 2005 and 2016. Baseline clinical and echocardiographic characteristics were compared among patients with and without myocardial fibrosis by cardiomyopathy type. Among the 332 LVAD core specimens, myocardial fibrosis was present in 79%. Myocardial fibrosis was more common in ischemic than in nonischemic patients (90% vs. 66%; p < 0.001). Patients with fibrosis were older than those without (58 ± 12 vs. 55 ± 19; p < 0.05). Among the nonischemic cardiomyopathy cases, those with fibrosis were more likely to have an implantable cardioverter defibrillator (ICD) 81% and to be diabetic 81%. Fibrosis was not associated with left ventricular end-diastolic diameter (LVEDD), creatinine, or N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). Myocardial fibrosis by apical core biopsy correlated with several known markers of left ventricular recovery including cardiomyopathy type, age, and presence of an ICD. In nonischemic cardiomyopathy patients, the degree of myocardial fibrosis may add information regarding recovery potential.

AB - Myocardial fibrosis identified by apical core pathology at the time of left ventricular assist device (LVAD) implantation may add information regarding myocardial recovery potential. In this analysis, we report the prevalence of myocardial fibrosis by cardiomyopathy type and its association with other known markers of left ventricular recovery. Left ventricular assist device core pathology was reviewed on 332 patients who underwent LVAD implantation at a single institution between 2005 and 2016. Baseline clinical and echocardiographic characteristics were compared among patients with and without myocardial fibrosis by cardiomyopathy type. Among the 332 LVAD core specimens, myocardial fibrosis was present in 79%. Myocardial fibrosis was more common in ischemic than in nonischemic patients (90% vs. 66%; p < 0.001). Patients with fibrosis were older than those without (58 ± 12 vs. 55 ± 19; p < 0.05). Among the nonischemic cardiomyopathy cases, those with fibrosis were more likely to have an implantable cardioverter defibrillator (ICD) 81% and to be diabetic 81%. Fibrosis was not associated with left ventricular end-diastolic diameter (LVEDD), creatinine, or N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). Myocardial fibrosis by apical core biopsy correlated with several known markers of left ventricular recovery including cardiomyopathy type, age, and presence of an ICD. In nonischemic cardiomyopathy patients, the degree of myocardial fibrosis may add information regarding recovery potential.

KW - biomarkers

KW - fibrosis

KW - left ventricular assist device

KW - myocardial recovery

UR - http://www.scopus.com/inward/record.url?scp=85060609278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060609278&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000774

DO - 10.1097/MAT.0000000000000774

M3 - Article

C2 - 29533251

AN - SCOPUS:85060609278

VL - 65

SP - 123

EP - 126

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 2

ER -